θ爆发式重复经颅磁刺激改善精神分裂症阴性症状与认知症状:双盲假对照随机临床试验研究方案
该研究为双盲假对照随机临床试验方案,拟纳入90例18至55岁伴阴性症状的精神分裂症受试者,按1:1随机接受活性或假θ爆发式刺激,同时刺激左侧背外侧前额叶与小脑蚓部,每日1800+1800个刺激、连续4周,主要终点为PANSS阴性症状严重度变化,并评估认知灵活性与安全性。
要点
- 方案采用θ爆发式刺激同时作用于左侧背外侧前额叶和小脑蚓部,每日各1800个刺激,连续4周。
- 主要终点为PANSS测量的阴性症状严重度变化,次要终点包括认知灵活性、执行功能、短时记忆、社会认知与面部情绪识别。
- 安全性结局为严重不良事件数量,研究为双盲假对照随机设计。
核心结论
- 作者假设接受活性治疗的受试者社会认知与阴性症状较假刺激组显著改善。
研究设计与样本
- 双盲、假对照、随机医疗器械研究方案,拟纳入90例18至55岁伴阴性症状的精神分裂症受试者,按1:1随机分配至活性刺激组与假刺激组。
主要发现
- TBS参数遵循标准TBS方案:每200毫秒给予3脉冲50赫兹爆发(即5赫兹),强度为100%活动运动阈值。
- 计划每日对左侧背外侧前额叶给予1800个刺激、对小脑蚓部给予1800个刺激,分两个9.5分钟区块,连续4周。
- 疗效分析采用线性混合模型,以疗效变量相对基线的差值为因变量,治疗组、访视及治疗×访视交互为自变量。
关键数值与推荐
- 主要终点为阳性与阴性症状量表(PANSS)测量的阴性症状严重度变化。
- 次要疗效终点为认知灵活性、执行功能、短时记忆、社会认知与面部情绪识别的变化。
- 安全性结局为严重不良事件数量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment effects of conventional approaches with antipsychotics or psychosocial interventions are limited when it comes to reducing negative and cognitive symptoms in schizophrenia. While there is emerging clinical evidence that new, augmented protocols based on theta-burst stimulation can increase rTMS efficacy dramatically in depression, data on similar augmented therapies are limited in schizophrenia. The different patterns of network impairments in subjects may underlie that some but not all patients responded to given stimulation locations. METHODS: Therefore, we propose an augmented theta-burst stimulation protocol in schizophrenia by stimulating both locations connected to negative symptoms: (1) the left dorsolateral prefrontal cortex (DLPFC), and (2) the vermis of the cerebellum. Ninety subjects with schizophrenia presenting negative symptoms and aging between 18 and 55 years will be randomized to active and sham stimulation in a 1:1 ratio. The TBS parameters we adopted follow the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 100% active motor threshold. We plan to deliver 1800 stimuli to the left DLPFC and 1800 stimuli to the vermis daily in two 9.5-min blocks for 4 weeks. The primary endpoint is the change in negative symptom severity measured by the Positive and Negative Syndrome Scale (PANSS). Secondary efficacy endpoints are changes in cognitive flexibility, executive functioning, short-term memory, social cognition, and facial emotion recognition. The difference between study groups will be analyzed by a linear mixed model analysis with the difference relative to baseline in efficacy variables as the dependent variable and treatment group, visit, and treatment-by-visit interaction as independent variables. The safety outcome is the number of serious adverse events. DISCUSSION: This is a double-blind, sham-controlled, randomized medical device study to assess the efficacy and safety of an augmented theta-burst rTMS treatment in schizophrenia. We hypothesize that social cognition and negative symptoms of patients on active therapy will improve significantly compared to patients on sham treatment. TRIAL REGISTRATION: The study protocol is registered at "ClinicalTrials.gov" with the following ID: NCT05100888. All items from the World Health Organization Trial Registration Data Set are registered. Initial release: 10/19/2021.
引用
- Csukly G, Orbán-Szigeti B, Suri K, et al. Theta-burst rTMS in schizophrenia to ameliorate negative and cognitive symptoms: study protocol for a double-blind, sham-controlled, randomized clinical trial. Trials. 2024. PMID: 38632647. doi:10.1186/s13063-024-08106-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。